Cures are already here — they just aren’t evenly distributed.
Some of the most innovative, life-saving therapies are also the most expensive. For example, Lenmeldy, a potentially curative therapy for Metachromatic leukodystrophy (MLD), carries a list price of $4.25 million per dose, making it the most expensive therapy in the world. Lenmeldy is not an outlier: many cell & gene therapies carry million-dollar price tags for a single dose.
The problem is that, given the current healthcare payment and care infrastructure, the distribution and administration of these treatments is both incredibly inefficient, and a terrible experience for patients and providers, alike:
- Insurance limitations: These therapies generate benefits that accrue over a lifetime, but today the price must be paid upfront, often by employers or health insurers who may only employ or cover a patient for a few years.
- Patient access burden: Rounds of prior authorizations and negotiations between care providers and payors delay patient care. Moreover, accessing these therapies may require distant travel and long-term stays in one of a few select hospitals, which can be out of reach financially and logistically for many patients.
- Care delivery complexity: These curative therapies are expensive to make and complex to administer, requiring heavy oversight from clinicians both pre- and post-administration. Providers often have to purchase the therapy upfront and bear the insurance reimbursement risk themselves.
Enter Aradigm: the infrastructure layer for the cure-based era of healthcare.
While traditional employer-sponsored plans treat these life-saving treatments as (very) expensive one-offs, Aradigm Health is building a care and coverage ecosystem tailor-made for these kinds of breakthroughs. By pooling risks and resources specific to these patients, Aradigm offers economies of scale, domain expertise, and an orchestration layer that traditional models lack. The net result is both dramatically more efficient (and less costly) care, but also a vastly improved patient experience whereby “navigating the system” is no longer a fulltime job by itself.
Aradigm ensures patients receive efficient, high-quality access to advanced therapeutic approaches by
- aggregating a group of employers and insurers to effectively pool risk and reduce premiums;
- convening a network of specialized providers and manufacturers to negotiate preferred pricing and financing, and create a shared knowledge-base for both patients and providers, alike;
- orchestrating all stakeholders through the patient journey in a way that reduces the logistical burden of accessing, administering, and, ultimately, paying for life-saving care.
Today we are thrilled to invest in Aradigm’s Series A financing, after leading the company’s seed round in 2024. We backed Aradigm at inception because we believed the gap between clinical innovation and financial innovation would become one of the defining challenges between the fields of bio & health—and that this team was uniquely positioned to solve it. They’ve since developed a first-of-its-kind platform with support of 15 of the nation’s largest employers and six leading payors. We’re proud to continue our partnership as they build the backbone that ensures these therapies are broadly accessible to patients.
We couldn’t imagine a better team to build this company. Aradigm’s founder and CEO, Dr. Will Shrank, has dedicated his entire career advancing patient access from every angle — at Humana and UPMC Health Plan as their Chief Medical Officer, at the Center for Medicare & Medicaid Services (CMS) designing early value-based payment models, at CVS Health shaping care delivery partnerships across retail, pharmacy, and risk-bearing systems, and at Harvard Medical School leading research programs on medication adherence challenges. He has also been a practicing physician, a startup advisor, and a venture partner with us at a16z where he was instrumental in our pursuit of this thesis over the past few years. Will has teamed up with Spencer Carrucciu, a repeat healthcare company builder and product leader, Annie Collins, our superstar former a16z healthcare investing colleague, and Justus Ruff, a skilled network operations leader from our portfolio company Pearl Health. Partnering with this incredible team to expand access to life-changing therapies has been a privilege.
The cure-based era of medicine needs new infrastructure. Aradigm is building it.
- Infinite Healthcare: What’s It Worth? Jay Rughani, Jane Rhee, and Julie Yoo
- Investing in Truemed Daisy Wolf, Julie Yoo, and Eva Steinman
- Investing in Leona Julie Yoo, Jay Rughani, and Eva Steinman
- Investing in Counsel Health Julie Yoo and Jay Rughani
- Investing in Fortuna Health Julie Yoo, Daisy Wolf, Eva Steinman, and Jane Rhee
- Infinite Healthcare: What’s It Worth? Jay Rughani, Jane Rhee, and Julie Yoo
- Investing in Truemed Daisy Wolf, Julie Yoo, and Eva Steinman
- Investing in Leona Julie Yoo, Jay Rughani, and Eva Steinman
- Investing in Counsel Health Julie Yoo and Jay Rughani
- Investing in Fortuna Health Julie Yoo, Daisy Wolf, Eva Steinman, and Jane Rhee